The service of Raymond James has provided a service to the Einschätzung of uniQure BV (NASDAQ: QURE) vor. The action moving from “Outperform” to “Strong Buy” is high, with the German price rising from US$20.00 to US$52.00.


The action is characterized by strong momentum and continues in the transition period which quickly reaches 14%. Laut InvestingPro-Daten helped analysts gain earnings figures for the coming period after correcting them. The next step is the next step in the development of biotechnology unternehmens: gene therapy products AMT-130 with treatment of Huntington’s Disease.


UniQure assumes that it is an application from the US Food and Drug Administration (FDA) for a rusk regulation of the AMT-130. Using a concrete batching plant, the Unified Huntington’s Disease Rating Scale (cUHDRS) is combined with an external control group as an intermediate clinical endpoint for the ZULASSUNGSPOWER technology used. Remarks are based on the fact that the FDA has engaged in the clinical investigation of the Biological License Application (BLA) application to be conducted.


The Unternehmen plant, in the first half of the year 2025, is one of the best technical studies with the FDA, a technical recovery study, the statistical analysis plans and the designs for a best study or research into market forces. A detailed update of the planned timetable has been carried out following this change. The InvestingPro Analysis said that it is a fair set of financial investments, while the liquid assets experience the highest interest payouts, while the cash reserves are suspended.


The analyst from Raymond James has discovered that the data from the cUHDRS together with the reduction of the neurofilament proteins in the drink (CSF NfL) have been developed for a beschleunigte Zulassung of AMT-130. The market volume for Huntington’s disease management in the United States was worth 2 million US dollars, an unmistakable Wachstum sauce for a unique past, which yielded a market capitalization of approximately 700 million US dollars.


That Optimismus is reflected in the active view and the higher price becomes wider. For more information about the uniQure and more than 10 exclusive analyst tips. InvestPro.


In other cases, uniQure NV has submitted an application to the FDA that involves a number of studies into the gene therapy AMT-130, a treatment for Huntington’s disease. This Entwicklung would yield positive results by the Finanzdienstleister Stifel. There is a Phase I/II clinical trial for the treatment of AMT-162 with the treatment of ALS, which has shown potential during the SOD1 mutations.


Raymond James’ messaging stats all felt that an “Outperform” assertion was where HC Wainwright and Stifel would get their “Buy” assertion for the outside market. I found a new solution that reduces a unique business by 65% ​​and a general sales manufacturing company in Lexington, Massachusetts.


These young mirrors of the fortress of the Unternehmens at the Entwicklung of Gene Therapies are becoming wider, with the Schwerpunkt lying on the AMT-130 for Huntington-Krankheit and the AMT-162 for ALS. We are moving forward with the FDA for the first half of the 2025s, a statistical analysis plan and technical study for the application of the biological license application for AMT-130 for the application.


This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.




Sitemap of nruklidmvq.medipunto.ru

Cannabis News RSS Feeds: Weedrss.com

1000+ unique media and news posts every 24 hours…

Published 2 hours ago
Published 7 hours ago
Published 13 hours ago
Published 16 hours ago
Published 17 hours ago
Published 17 hours ago
Published 20 hours ago
Published 21 hours ago
Published 21 hours ago
Published 21 hours ago
Published 22 hours ago